Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Precision BioSciences held an investor update on March 17, 2026 focused on its PBGENE-DMD program, featuring management (Naresh Tanna; CFO referenced as John/Alex Kelly; CSO Cassie Gorsuch) and key opinion leaders Pat Furlong and Dr. Veerapandiyan. The call was a recorded investor briefing with no new clinical or financial metrics disclosed; management reiterated that remarks contained forward‑looking statements and directed listeners to the company’s 10-K/10-Q for risk factors.

Analysis

Precision’s DMD program sits at an inflection where a single durable efficacy readout would reprice not only DTIL but also the broader in vivo gene‑editing cohort; conversely, a safety or durability miss would disproportionately compress valuations for smaller-cap editing names while leaving big AAV-replacement franchises relatively insulated. Expect second-order winners: contract manufacturers and CRISPR/endonuclease reagent suppliers if ARCUS‑style editing scales, and losers among pure-play AAV vector capacity providers if single-dose gene editing displaces repeat-dosing replacement strategies.

Key risks compress into three levers with distinct horizons: near-term (weeks–months) safety/immune signals that can move shares violently; medium-term (6–18 months) durability and functional outcome readthrough that determine commercial optionality; and long-term (years) regulatory precedent around re‑dosing and off‑target genomics that shape TAM capture. A single serious adverse event or manufacturing failure could reverse optimism nearly overnight; conversely, even surrogate biomarker improvements tied to clinically meaningful endpoints could unlock accelerated pathways and multiple expansion.

Market positioning looks misaligned: the current implied volatility and bid for optionality suggests investors are buying binary upside but under-hedging the asymmetric downside tied to immunogenicity and durability. That makes structured, time‑boxed option exposure (capped risk, levered upside) and relative-value pair trades against AAV-centric peers the highest-conviction ways to express a view while avoiding naked directional gamma into event weeks.

Key Decisions for Investors

• Buy DTIL 12‑18 month call spread (buy ~30‑delta, sell ~60‑delta) sized 1–2% of portfolio notional as event‑driven exposure to upcoming safety/efficacy data; target 2.5–4x payoff if positive signals materialize, max loss = premium paid, time decay mitigated by selling the short leg.
• Pair trade: long DTIL (equity or call spread as above) vs short SRPT (size ~0.5x DTIL notional) over 6–12 months to isolate modality arbitrage between gene editing and AAV replacement; thesis wins if editing demonstrates superior single‑dose durability or safety, expected asymmetric payoff with capped downside if SRPT outperforms.
• Buy protective tail (OTM puts) sized to 50% of long exposure for DTIL over the next 3 months to guard against adverse safety headlines; acceptable cost ~1–2% portfolio to limit event risk that could wipe out binary long positions.
• If implied volatility collapses after an initial de‑risking rally, consider selling short‑dated calls to finance rolling longer-dated call spreads (calendar structure) to maintain upside exposure while monetizing transient IV — use only after clear safety signals and size to keep net delta modest.